What Happened?

Shares of genetic testing company Myriad Genetics (NASDAQ: MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of its cancer tests in India. 

Under the terms of the deal, Zydus planned to introduce Myriad's MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris Prostate Cancer Prognostic Test to patients and doctors across the country. The partnership marked a significant step in expanding precision oncology services for Indian patients. This collaboration was designed to improve clinician education and the diagnostic framework, allowing patients to benefit from earlier, more accurate risk assessment and more confident treatment planning. For Myriad, the agreement represented an important move to grow its presence in a major international market.

After the initial pop the shares cooled down to $6.80, up 3.7% from previous close.

Is now the time to buy Myriad Genetics? Access our full analysis report here.

What Is The Market Telling Us

Myriad Genetics’s shares are extremely volatile and have had 42 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 13 days ago when the stock gained 2.5% on the news that the company announced it would present new data from eight studies at the 2025 San Antonio Breast Cancer Symposium. The presentation focused on advances in its MyRisk® Hereditary Cancer Test and its Precise® Molecular Residual Disease (MRD) Test. The research supported treatment decisions guided by medical standards, especially for breast cancer. The company highlighted its MRD test as a highly sensitive tool for detecting cancer, which is particularly useful for cancers that are difficult to track. A company executive noted they were sharing "very strong data," which suggested positive results from their studies.

Myriad Genetics is down 49.7% since the beginning of the year, and at $6.80 per share, it is trading 54.6% below its 52-week high of $14.98 from February 2025. Investors who bought $1,000 worth of Myriad Genetics’s shares 5 years ago would now be looking at an investment worth $366.11.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.